Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: METASTATIC MELANOMA, . Treffer: 60

2018

Richtig, G; Hoeller, C; Wolf, M; Wolf, I; Rainer, BM; Schulter, G; Richtig, M; Grübler, MR; Gappmayer, A; Haidn, T; Kofler, J; Huegel, R; Lange-Asschenfeldt, B; Pichler, M; Pilz, S; Heinemann, A; Richtig, E Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study.
PLoS One. 2018; 13(10): e0204729-e0204729. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2017

Kandolf Sekulovic, L; Peris, K; Hauschild, A; Stratigos, A; Grob, JJ; Nathan, P; Dummer, R; Forsea, AM; Hoeller, C; Gogas, H; Demidov, L; Lebbe, C; Blank, C; Olah, J; Bastholt, L; Herceg, D; Neyns, B; Vieira, R; Hansson, J; Rutkowski, P; Krajsova, I; Bylaite-Bucinskiene, M; Zalaudek, I; Maric-Brozic, J; Babovic, N; Banjin, M; Putnik, K; Weinlich, G; Todorovic, V; Kirov, K; Ocvirk, J; Zhukavets, A; Kukushkina, M; De La Cruz Merino, L; Ymeri, A; Risteski, M; Garbe, C More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
Eur J Cancer. 2017; 75(4):313-322
Web of Science PubMed FullText FullText_MUG

 

Richtig, G; Ehall, B; Richtig, E; Aigelsreiter, A; Gutschner, T; Pichler, M Function and Clinical Implications of Long Non-Coding RNAs in Melanoma.
Int J Mol Sci. 2017; 18(4): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Ugurel, S; Loquai, C; Terheyden, P; Schadendorf, D; Richtig, E; Utikal, J; Gutzmer, R; Rass, K; Sunderkotter, C; Stein, A; Fluck, M; Kaatz, M; Trefzer, U; Kahler, K; Stadler, R; Berking, C; Holler, C; Kerschke, L; Edler, L; Kopp-Schneider, A; Becker, JC Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial
ONCOTARGET. 2017; 8(44): 76029-76043. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Busam, KJ; Vilain, RE; Lum, T; Busam, JA; Hollmann, TJ; Saw, RP; Coit, DC; Scolyer, RA; Wiesner, T Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation.
Am J Surg Pathol. 2016; 40(6):786-795 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Hügel, R; Muendlein, A; Volbeding, L; Drexel, H; Richtig, E; Wehkamp, U; Painsi, C; Lange-Asschenfeldt, B; Hauschild, A; Egberts, F Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma.
Melanoma Res. 2016; 26(4):354-360
Web of Science PubMed FullText FullText_MUG

 

Partl, R; Fastner, G; Kaiser, J; Kronhuber, E; Cetin-Strohmer, K; Steffal, C; Böhmer-Breitfelder, B; Mayer, J; Avian, A; Berghold, A KPS/LDH index: a simple tool for identifying patients with metastatic melanoma who are unlikely to benefit from palliative whole brain radiotherapy.
Support Care Cancer. 2016; 24(2):523-528 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Richtig, G; Aigelsreiter, A; Kashofer, K; Talakic, E; Kupsa, R; Schaider, H; Richtig, E Two Case Reports of Rare BRAF Mutations in Exon 11 and Exon 15 with Discussion of Potential Treatment Options.
Case Rep Oncol. 2016; 9(3):543-546 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Trapp, EM; Trapp, M; Avian, A; Rohrer, PM; Weissenböck, T; Kapfhammer, HP; Demel, U; Linder, MD; Kresse, A; Richtig, E Association of Stress Coping Strategies with Immunological Parameters in Melanoma Patients.
ACTA DERM-VENEREOL. 2016; 96(217): 74-77. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Willmes, C; Kumar, R; Becker, JC; Fried, I; Rachakonda, PS; Poppe, LM; Hesbacher, S; Schadendorf, D; Sucker, A; Schrama, D; Ugurel, S SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma.
Oncotarget. 2016; 7(9): 10117-10132. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2015

Køllgaard, T; Ugurel-Becker, S; Idorn, M; Andersen, MH; Becker, JC; Straten, PT Pre-Vaccination Frequencies of Th17 Cells Correlate with Vaccine-Induced T-Cell Responses to Survivin-Derived Peptide Epitopes.
PLoS One. 2015; 10(7):e0131934-e0131934 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Machan, S; El Shabrawi-Caelen, L; Nikolay, E; Kerl, H; Requena, L; Cerroni, L Follicular malignant melanoma: primary follicular or folliculotropic?
Am J Dermatopathol. 2015; 37(1):15-19 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Piana, S; Tagliavini, E; Ragazzi, M; Zanelli, M; Zalaudek, I; Ciarrocchi, A; Valli, R Lymph node melanocytic nevi: pathogenesis and differential diagnoses, with special reference to p16 reactivity.
Pathol Res Pract. 2015; 211(5):381-388
Web of Science PubMed FullText FullText_MUG

 

Ugurel, S; Loquai, C; Kähler, K; Hassel, J; Berking, C; Zimmer, L; Haubitz, I; Satzger, I; Müller-Brenne, T; Mikhaimer, NC; Becker, JC; Kilian, KJ; Schadendorf, D; Heinzerling, L; Kaatz, M; Utikal, J; Göppner, D; Pföhler, C; Pflugfelder, A; Mössner, R; Gutzmer, R; Dermatologic Cooperative Oncology Group (DeCOG) A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival.
Ann Oncol. 2015; 26(3):573-582 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2014

Goldinger, SM; Zimmer, L; Schulz, C; Ugurel, S; Hoeller, C; Kaehler, KC; Schadendorf, D; Hassel, JC; Becker, J; Hauschild, A; Dummer, R; Dermatology Cooperative Oncology Group (DeCOG) Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Eur J Cancer. 2014; 50(2):406-410
Web of Science PubMed FullText FullText_MUG

 

Richtig, G; Richtig, E; Massone, C; Hofmann-Wellenhof, R Analysis of clinical, dermoscopic and histopathological features of primary melanomas of patients with metastatic disease--a retrospective study at the Department of Dermatology, Medical University of Graz, 2000-2010.
J Eur Acad Dermatol Venereol. 2014; 28(12):1776-1781
Web of Science PubMed FullText FullText_MUG

 

2013

Degen, A; Weichenthal, M; Ugurel, S; Trefzer, U; Kilian, K; Garbe, C; Egberts, F; Poppe, LM; Hauschild, A; Gutzmer, R Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
J Dtsch Dermatol Ges. 2013; 11(9):846-853
Web of Science PubMed FullText FullText_MUG

 

2012

Liu, SJ; Tetzlaff, MT; Liu, AH; Liegl-Atzwanger, B; Guo, J; Xu, XW; Loss of microRNA-205 expression is associated with melanoma progression.
Lab Invest. 2012; 92(7):1084-1096 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Egberts, F; Gutzmer, R; Ugurel, S; Becker, JC; Trefzer, U; Degen, A; Schenck, F; Frey, L; Wilhelm, T; Hassel, JC; Schadendorf, D; Livingstone, E; Mauch, C; Garbe, C; Berking, C; Rass, K; Mohr, P; Kaehler, KC; Weichenthal, M; Hauschild, A Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Ann Oncol. 2011; 22(7):1667-1674 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Ugurel, S; Becker, JC [Treatment of advanced metastatic melanoma].
Hautarzt. 2011; 62(6):423-429
Web of Science PubMed FullText FullText_MUG

 

2008

Giacomel, J; Zalaudek, I; Mordente, I; Nicolino, R; Argenziano, G Never perform laser treatment of skin tumors with clinical EFG criteria.
J Dtsch Dermatol Ges. 2008; 6(5):386-388 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Hauschild, A; Dummer, R; Ugurel, S; Kaehler, KC; Egberts, F; Fink, W; Both-Skalsky, J; Laetsch, B; Schadendorf, D Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
Cancer. 2008; 113(6):1404-1411 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hauschild, A; Trefzer, U; Garbe, C; Kaehler, KC; Ugurel, S; Kiecker, F; Eigentler, T; Krissel, H; Schott, A; Schadendorf, D Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Melanoma Res. 2008; 18(4):274-278
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Spieth, K; Kaufmann, R; Dummer, R; Garbe, C; Becker, JC; Hauschild, A; Tilgen, W; Ugurel, S; Beyeler, M; Bröcker, EB; Kaehler, KC; Pföhler, C; Gille, J; Leiter, U; Schadendorf, D Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Ann Oncol. 2008; 19(4):801-806 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2007

Matharoo-Ball, B; Ratcliffe, L; Lancashire, L; Ugurel, S; Miles, AK; Weston, DJ; Rees, R; Schadendorf, D; Ball, G; Creaser, CS Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI-TOF mass spectrometry/bioinformatic approach.
Proteomics Clin Appl. 2007; 1(6):605-620
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Seidl, H; Richtig, E; Tilz, H; Stefan, M; Schmidbauer, U; Asslaber, M; Zatloukal, K; Herlyn, M; Schaider, H Profiles of chemokine receptors in melanocytic lesions: de novo expression of CXCR6 in melanoma.
Hum Pathol. 2007; 38(5):768-780
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2006

Hoek, KS; Schlegel, NC; Brafford, P; Sucker, A; Ugurel, S; Kumar, R; Weber, BL; Nathanson, KL; Phillips, DJ; Herlyn, M; Schadendorf, D; Dummer, R Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 2006; 19(4):290-302
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Schadendorf, D; Hauschild, A; Ugurel, S; Thoelke, A; Egberts, F; Kreissig, M; Linse, R; Trefzer, U; Vogt, T; Tilgen, W; Mohr, P; Garbe, C Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Ann Oncol. 2006; 17(10):1592-1597 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Thoelke, A; Schmid, HP; Figl, R; Schadendorf, D; Ugurel, S Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanoma.
Eur J Dermatol. 2006; 16(4):428-430 (- Case Report) [OPEN ACCESS]
Web of Science PubMed Google Scholar

 

2005

Kaufmann, R; Spieth, K; Leiter, U; Mauch, C; von den Driesch, P; Vogt, T; Linse, R; Tilgen, W; Schadendorf, D; Becker, JC; Sebastian, G; Krengel, S; Kretschmer, L; Garbe, C; Dummer, R Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
J Clin Oncol. 2005; 23(35):9001-9007 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Richtig, E; Ludwig, R; Kerl, H; Smolle, J Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
BRIT J DERMATOL. 2005; 153(5): 925-931.
Web of Science PubMed FullText FullText_MUG

 

Richtig, E; Soyer, HP; Posch, M; Mossbacher, U; Bauer, P; Teban, L; Svolba, G; Wolf, IH; Fritsch, P; Zelger, B; Volc-Platzer, B; Gebhart, W; Mischer, P; Steiner, A; Pachinger, W; Hintner, H; Gschnait, F; Rappersberger, K; Pilarski, P; Pehamberger, H; European Cooperative Adjuvant Melanoma Treatment Study Group Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
J Clin Oncol. 2005; 23(34):8655-8663 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Ugurel, S; Hildenbrand, R; Zimpfer, A; La Rosee, P; Paschka, P; Sucker, A; Keikavoussi, P; Becker, JC; Rittgen, W; Hochhaus, A; Schadendorf, D Lack of clinical efficacy of imatinib in metastatic melanoma.
Br J Cancer. 2005; 92(8):1398-1405 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG Google Scholar

 

Vetter, CS; Muller-Blech, K; Schrama, D; Brocker, EB; Becker, JC Cytoplasmic and nuclear expression of survivin in melanocytic skin lesions.
Arch Dermatol Res. 2005; 297(1):26-30
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2004

Andersen, MH; Fensterle, J; Ugurel, S; Reker, S; Houben, R; Guldberg, P; Berger, TG; Schadendorf, D; Trefzer, U; Brocker, EB; Straten, PT; Rapp, UR; Becker, JC Immunogenicity of constitutively active (V599E)BRaf
CANCER RES. 2004; 64(15): 5456-5460. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

de Giorgi, V; Massi, D; Brunasso, G; Salvini, C; Mastrolorenzo, A; Zuccati, G; Carli, P Eruptive multiple blue nevi of the penis: a clinical dermoscopic pathologic case study.
J Cutan Pathol. 2004; 31(2):185-188 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Helige, C; Hofmann-Wellenhof, R; Fink-Puches, R; Smolle, J Mofarotene-induced inhibition of melanoma cell motility by increasing vinculin-containing focal contacts.
MELANOMA RES. 2004; 14(6): 547-554.
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Richtig, E; Hofmann-Wellenhof, R; Pehamberger, H; Forstinger, Ch; Wolff, K; Mischer, P; Raml, J; Fritsch, P; Zelger, B; Ratzinger, G; Koller, J; Lang, A; Konrad, K; Kindermann-Glebowski, E; Seeber, A; Steiner, A; Fialla, R; Pachinger, W; Kos, C; Klein, G; Kehrer, H; Kerl, H; Ulmer, H; Smolle, J Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
BRIT J DERMATOL. 2004; 151(1): 91-98.
Web of Science PubMed FullText FullText_MUG

 

2003

Andersen, MH; Gehl, J; Reker, S; Pedersen, LO; Becker, JC; Geertsen, P; Straten, PT Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Semin Cancer Biol. 2003; 13(6):449-459
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Richtig, E; Hoff, M; Rehak, P; Kapp, K; Hofmann-Wellenhof, R; Zalaudek, I; Poschauko, J; Uggowitzer, M; Kohek, P; Smolle, J Efficacy of superficial and deep regional hyperthermia combined with systemic chemotherapy and radiotherapy in metastatic melanoma.
J Dtsch Dermatol Ges. 2003; 1(8):635-642
PubMed Google Scholar

 

Schaider, H; Oka, M; Bogenrieder, T; Nesbit, M; Satyamoorthy, K; Berking, C; Matsushima, K; Herlyn, M Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8.
Int J Cancer. 2003; 103(3):335-343
Web of Science PubMed FullText FullText_MUG

 

Ugurel, S; Schadendorf, D Systemic treatment in advanced melanoma: innovative perspectives.
Onkologie. 2003; 26(3):234-238
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Ugurel, S; Tilgen, W; Reinhold, U Chemosensitivity testing in malignant melanoma.
Recent Results Cancer Res. 2003; 161(8):81-92
PubMed

 

2002

Wack, C; Kirst, A; Becker, JC; Lutz, WK; Brocker, EB; Fischer, WH Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
Cancer Immunol Immunother. 2002; 51(8):431-439
Web of Science PubMed FullText FullText_MUG

 

2001

Fink-Puches, R; Pilarski, P; Schmidbauer, U; Kerl, H; Soyer, HP No evidence for c-erbB-2 overexpression in cutaneous melanoma.
Anticancer Res. 2001; 21(4A):2793-2795
Web of Science PubMed Google Scholar

 

Hauschild, A; Garbe, C; Stolz, W; Ellwanger, U; Seiter, S; Dummer, R; Ugurel, S; Sebastian, G; Nashan, D; Linse, R; Achtelik, W; Mohr, P; Kaufmann, R; Fey, M; Ulrich, J; Tilgen, W Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Br J Cancer. 2001; 84(8):1036-1042 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Rappl, G; Hasselmann, DO; Rössler, M; Ugurel, S; Tilgen, W; Reinhold, U Detection of tumor-associated circulating mRNA in patients with disseminated malignant melanoma.
Ann N Y Acad Sci. 2001; 945(5):189-191
Web of Science PubMed

 

1999

Terheyden, P; Siedel, C; Merkel, A; Kampgen, E; Brocker, EB; Becker, JC Predominant expression of Fas (CD95) ligand in metastatic melanoma revealed by longitudinal analysis.
J Invest Dermatol. 1999; 112(6):899-902 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1998

Pehamberger, H; Soyer, HP; Steiner, A; Kofler, R; Binder, M; Mischer, P; Pachinger, W; Auböck, J; Fritsch, P; Kerl, H; Wolff, K Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.
J Clin Oncol. 1998; 16(4):1425-1429 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Trcka, J; Kampgen, E; Becker, JC; Schwaaf, A; Brocker, EB Immunochemotherapy of malignant melanoma. Epifocal administration of dinitrochlorobenzene (DNCB) combined with systemic chemotherapy with dacarbazine (DTIC)
Hautarzt. 1998; 49(1):17-22
Web of Science PubMed FullText FullText_MUG

 

Weitere 50 Treffer anzeigen
© Med Uni Graz Impressum